Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.72 |
| ▸ | DRD4 | P21917 | 3/20 | 0.72 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6933599 | 0.88 | DRD2 (0.69) | DRD2DRD4HTR1AADRA1A | |
| SCHEMBL7607694 | 0.87 | DRD2 (0.67) | DRD2DRD4DRD3HTR1AADRA1A | |
| SCHEMBL6933580 | 0.86 | HTR1A (0.71) | DRD2DRD4HTR1AADRA1A | |
| SCHEMBL6928363 | 0.84 | DRD2 (0.64) | DRD2DRD4 | |
| SCHEMBL6930794 | 0.82 | DRD2 (0.66) | DRD2DRD4DRD3HTR1AADRA1A | |
| SCHEMBL10911858 | 0.81 | DRD2 (0.85) | DRD2DRD4DRD3HTR1AADRA1A | |
| SCHEMBL11446717 | 0.80 | HTR1A (0.75) | DRD2DRD4DRD3HTR1A | |
| Hydrochloric Acid SCHEMBL9026537 | 0.80 | HTR1A (0.63) | DRD2DRD4HTR1AADRA1A | |
| SCHEMBL10910897 | 0.80 | DRD2 (0.83) | DRD2DRD4DRD3HTR1AADRA1A | |
| SCHEMBL10808759 | 0.80 | DRD2 (0.83) | DRD2DRD4DRD3HTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | claimed |
| EP-1000047-A1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006384-A1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-02-11 | — | — | WO | claimed |
| EP-1000047-B1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI CHEM PHARM (CH) | 2003-12-17 | — | — | EP | disclosed |
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMOANY | 2002-12-19 | — | — | US | disclosed |
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | disclosed |
| US-6071920-A | BIND TO 5HT 1A RECEPTORS FOR TREATING DISORDERS OF THE LOWER URINARY TRACT; CNS DISORDERS; ANXIOLYTIC AGENTS; ANTIDEPRESSANTS; HYPOTENSIVE AGENTS; SLEEP AND EATING DISORDERS | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2000-06-06 | — | — | US | disclosed |
| EP-1000047-A1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006384-A1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | NLN, GLS, CPT1B | DRD2 1479/4885DRD4 2385/4885DRD3 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.